These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. Chavanet P, Lopez J, Grappin M, Bonnin A, Duong M, Waldner A, Buisson M, Camerlynck P, Portier H. AIDS; 1994 Jul; 8(7):945-50. PubMed ID: 7946104 [Abstract] [Full Text] [Related]
4. Dynamic analysis of oral Candida carriage, distribution, and antifungal susceptibility in HIV-infected patients during the first year of highly active antiretroviral therapy in Guangxi, China. Jiang L, Yong X, Li R, Peng Y, Liu W, Qin Q, Zhang L, Liu Z, Liang H, Tao R. J Oral Pathol Med; 2014 Oct; 43(9):696-703. PubMed ID: 24931443 [Abstract] [Full Text] [Related]
5. The prevalence, risk factors and antifungal sensitivity pattern of oral candidiasis in HIV/AIDS patients in Kumba District Hospital, South West Region, Cameroon. Ambe NF, Longdoh NA, Tebid P, Bobga TP, Nkfusai CN, Ngwa SB, Nsai FS, Cumber SN. Pan Afr Med J; 2020 Oct; 36():23. PubMed ID: 32774600 [Abstract] [Full Text] [Related]
6. Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China. Li YY, Chen WY, Li X, Li HB, Li HQ, Wang L, He L, Yang XP, Wang XC, Huang YL, Yao YG. BMC Infect Dis; 2013 Jan 28; 13():46. PubMed ID: 23356471 [Abstract] [Full Text] [Related]
9. Oral Candida isolates among HIV-infected subjects in Nigeria. Nweze EI, Ogbonnaya UL. J Microbiol Immunol Infect; 2011 Jun 28; 44(3):172-7. PubMed ID: 21524610 [Abstract] [Full Text] [Related]
10. Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era. Costa CR, de Lemos JA, Passos XS, de Araújo CR, Cohen AJ, Souza LK, Silva Mdo R. Mycopathologia; 2006 Jul 28; 162(1):45-50. PubMed ID: 16830191 [Abstract] [Full Text] [Related]
13. Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Enwuru CA, Ogunledun A, Idika N, Enwuru NV, Ogbonna F, Aniedobe M, Adeiga A. Afr Health Sci; 2008 Sep 28; 8(3):142-8. PubMed ID: 19357740 [Abstract] [Full Text] [Related]
15. Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter. Wu CJ, Lee HC, Yang YL, Chang CM, Chen HT, Lin CC, Lee NY, Chu WL, Hsieh LY, Wang YL, Lauderale TL, Tseng FC, Ko NY, Ko WC, Lo HJ. Clin Microbiol Infect; 2012 May 28; 18(5):485-90. PubMed ID: 21939471 [Abstract] [Full Text] [Related]
17. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, Vazquez JA, Rampalo A, HIV Epidemiology Research Study (HERS) Group. J Infect Dis; 2001 Jan 15; 183(2):286-93. PubMed ID: 11204125 [Abstract] [Full Text] [Related]
19. Frequency of Candida spp. in the oral cavity of Brazilian HIV-positive patients and correlation with CD4 cell counts and viral load. Back-Brito GN, Mota AJ, Vasconcellos TC, Querido SM, Jorge AO, Reis AS, Balducci I, Koga-Ito CY. Mycopathologia; 2009 Feb 15; 167(2):81-7. PubMed ID: 18781394 [Abstract] [Full Text] [Related]